Cargando…
Capturing Measures That Matter: The Potential Value of Digital Measures of Physical Behavior for Alzheimer’s Disease Drug Development
Alzheimer’s disease (AD) is a devastating neurodegenerative disease and the primary cause of dementia worldwide. Despite the magnitude of AD’s impact on patients, caregivers, and society, nearly all AD clinical trials fail. A potential contributor to this high rate of failure is that established cli...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578291/ https://www.ncbi.nlm.nih.gov/pubmed/37545234 http://dx.doi.org/10.3233/JAD-230152 |
_version_ | 1785121490582110208 |
---|---|
author | Bachman, Shelby L. Blankenship, Jennifer M. Busa, Michael Serviente, Corinna Lyden, Kate Clay, Ieuan |
author_facet | Bachman, Shelby L. Blankenship, Jennifer M. Busa, Michael Serviente, Corinna Lyden, Kate Clay, Ieuan |
author_sort | Bachman, Shelby L. |
collection | PubMed |
description | Alzheimer’s disease (AD) is a devastating neurodegenerative disease and the primary cause of dementia worldwide. Despite the magnitude of AD’s impact on patients, caregivers, and society, nearly all AD clinical trials fail. A potential contributor to this high rate of failure is that established clinical outcome assessments fail to capture subtle clinical changes, entail high burden for patients and their caregivers, and ineffectively address the aspects of health deemed important by patients and their caregivers. AD progression is associated with widespread changes in physical behavior that have impacts on the ability to function independently, which is a meaningful aspect of health for patients with AD and important for diagnosis. However, established assessments of functional independence remain underutilized in AD clinical trials and are limited by subjective biases and ceiling effects. Digital measures of real-world physical behavior assessed passively, continuously, and remotely using digital health technologies have the potential to address some of these limitations and to capture aspects of functional independence in patients with AD. In particular, measures of real-world gait, physical activity, and life-space mobility captured with wearable sensors may offer value. Additional research is needed to understand the validity, feasibility, and acceptability of these measures in AD clinical research. |
format | Online Article Text |
id | pubmed-10578291 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | IOS Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-105782912023-10-17 Capturing Measures That Matter: The Potential Value of Digital Measures of Physical Behavior for Alzheimer’s Disease Drug Development Bachman, Shelby L. Blankenship, Jennifer M. Busa, Michael Serviente, Corinna Lyden, Kate Clay, Ieuan J Alzheimers Dis Review Alzheimer’s disease (AD) is a devastating neurodegenerative disease and the primary cause of dementia worldwide. Despite the magnitude of AD’s impact on patients, caregivers, and society, nearly all AD clinical trials fail. A potential contributor to this high rate of failure is that established clinical outcome assessments fail to capture subtle clinical changes, entail high burden for patients and their caregivers, and ineffectively address the aspects of health deemed important by patients and their caregivers. AD progression is associated with widespread changes in physical behavior that have impacts on the ability to function independently, which is a meaningful aspect of health for patients with AD and important for diagnosis. However, established assessments of functional independence remain underutilized in AD clinical trials and are limited by subjective biases and ceiling effects. Digital measures of real-world physical behavior assessed passively, continuously, and remotely using digital health technologies have the potential to address some of these limitations and to capture aspects of functional independence in patients with AD. In particular, measures of real-world gait, physical activity, and life-space mobility captured with wearable sensors may offer value. Additional research is needed to understand the validity, feasibility, and acceptability of these measures in AD clinical research. IOS Press 2023-09-12 /pmc/articles/PMC10578291/ /pubmed/37545234 http://dx.doi.org/10.3233/JAD-230152 Text en © 2023 – The authors. Published by IOS Press https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Bachman, Shelby L. Blankenship, Jennifer M. Busa, Michael Serviente, Corinna Lyden, Kate Clay, Ieuan Capturing Measures That Matter: The Potential Value of Digital Measures of Physical Behavior for Alzheimer’s Disease Drug Development |
title | Capturing Measures That Matter: The Potential Value of Digital Measures of Physical Behavior for Alzheimer’s Disease Drug Development |
title_full | Capturing Measures That Matter: The Potential Value of Digital Measures of Physical Behavior for Alzheimer’s Disease Drug Development |
title_fullStr | Capturing Measures That Matter: The Potential Value of Digital Measures of Physical Behavior for Alzheimer’s Disease Drug Development |
title_full_unstemmed | Capturing Measures That Matter: The Potential Value of Digital Measures of Physical Behavior for Alzheimer’s Disease Drug Development |
title_short | Capturing Measures That Matter: The Potential Value of Digital Measures of Physical Behavior for Alzheimer’s Disease Drug Development |
title_sort | capturing measures that matter: the potential value of digital measures of physical behavior for alzheimer’s disease drug development |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578291/ https://www.ncbi.nlm.nih.gov/pubmed/37545234 http://dx.doi.org/10.3233/JAD-230152 |
work_keys_str_mv | AT bachmanshelbyl capturingmeasuresthatmatterthepotentialvalueofdigitalmeasuresofphysicalbehaviorforalzheimersdiseasedrugdevelopment AT blankenshipjenniferm capturingmeasuresthatmatterthepotentialvalueofdigitalmeasuresofphysicalbehaviorforalzheimersdiseasedrugdevelopment AT busamichael capturingmeasuresthatmatterthepotentialvalueofdigitalmeasuresofphysicalbehaviorforalzheimersdiseasedrugdevelopment AT servientecorinna capturingmeasuresthatmatterthepotentialvalueofdigitalmeasuresofphysicalbehaviorforalzheimersdiseasedrugdevelopment AT lydenkate capturingmeasuresthatmatterthepotentialvalueofdigitalmeasuresofphysicalbehaviorforalzheimersdiseasedrugdevelopment AT clayieuan capturingmeasuresthatmatterthepotentialvalueofdigitalmeasuresofphysicalbehaviorforalzheimersdiseasedrugdevelopment |